Akonni Awarded $3.2M NIH Grant

Akonni Biosystems, a Frederick, Maryland-based molecular diagnostics company focused on providing scalable solutions for infectious disease testing, announced receipt of a $3.2m Phase II SBIR grant from the National Institutes of Health (NIH).
The award will enable Akonni to combine polymerase chain reaction (PCR) with its existing TruArray(R) gel-drop microarray in a single chamber, closed-amplicon system, and field test it for the detection of influenzas A and B and their antigenic subtypes, including antiviral resistant types.
The grant is based on the successful completion of an earlier Phase I SBIR, and has as a goal the production of commercial products for clinical and research laboratories.
Partnering with Akonni Biosystems are Wadsworth Center, Columbia University, Little Company of Mary Hospital, and the US Centers for Disease Control (CDC). 

Join the discussion